Nomura Holdings
CRSP icon

Nomura Holdings’s CRISPR Therapeutics CRSP Stock Holding History

Nomura Holdings’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$404K Buy
+8,500
New +$448K ﹤0.01% 1426
2025
Q2 		– Sell
-30,000
Closed -$1.02M – 1553
2025
Q1 		$1.02M Buy
+30,000
New +$1.27M ﹤0.01% 1270

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Nomura Holdings's CRSP Position: Q1 2026 in Review

Nomura Holdings opened a new position in CRISPR Therapeutics (CRSP) in Q1 2026: 5,273 shares worth $251K. The stake represents ﹤0.01% of the portfolio and ranks #1523 among its holdings. This is a return to the name: Nomura Holdings previously reported a position in CRSP as recently as Q1 2025.

Nomura Holdings first reported a position in CRSP in Q4 2023 and has held it in 3 quarters since. The position peaked at $905K in Q1 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Nomura Holdings held 5,273 shares of CRISPR Therapeutics worth $251K as of Q1 2026.
  • CRISPR Therapeutics was a new Nomura Holdings position in Q1 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Nomura Holdings's portfolio in Q1 2026, its #1523 holding.
  • Nomura Holdings first reported a position in CRISPR Therapeutics in Q4 2023 and has held it in 3 quarters since.
  • Nomura Holdings's CRISPR Therapeutics position peaked at $905K in Q1 2025.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Nomura Holdings's 13F filing for Q1 2026, filed 15 May 2026.